참고문헌
- Dussault PM, Lazzari AA. Epilepsy and osteoporosis risk. Curr Opin Endocrinol Diabetes Obes 2017;24:395-401. https://doi.org/10.1097/MED.0000000000000366
- van Karnebeek CDM, Wortmann SB, Tarailo-Graovac M, Langeveld M, Ferreira CR, van de Kamp JM, et al. The role of the clinician in the multi-omics era: are you ready? J Inherit Metab Dis 2018;41:571-82. https://doi.org/10.1007/s10545-017-0128-1
- Williams N, Challoumas D, Ketteridge D, Cundy PJ, Eastwood DM. The mucopolysaccharidoses: advances in medical care lead to challenges in orthopaedic surgical care. Bone Joint J 2017;99-b:1132-9. https://doi.org/10.1302/0301-620X.99B9.BJJ-2017-0487
- Cimaz R, Vijay S, Haase C, Coppa GV, Bruni S, Wraith E, et al. Attenuated type I mucopolysaccharidosis in the differential diagnosis of juvenile idiopathic arthritis: a series of 13 patients with Scheie syndrome. Clin Exp Rheumatol 2006;24:196-202.
- Mikosch P, Hughes D. An overview on bone manifestations in Gaucher disease. Wien Med Wochenschr 2010;160:609-24. https://doi.org/10.1007/s10354-010-0841-y
- Fonta C, Salles JP. Neuromuscular features of hypophosphatasia. Arch Pediatr 2017;24:5s85-5s8.
- Millan JL, Whyte MP. Alkaline Phosphatase and Hypophosphatasia. Calcif Tissue Int 2016;98:398-416. https://doi.org/10.1007/s00223-015-0079-1
- Conti F, Ciullini L, Pugliese G. Hypophosphatasia: clinical manifestation and burden of disease in adult patients. Clin Cases Miner Bone Metab 2017;14:230-4. https://doi.org/10.11138/ccmbm/2017.14.1.230
- Whyte MP, Greenberg CR, Salman NJ, Bober MB, McAlister WH, Wenkert D, et al. Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med 2012;366:904-13. https://doi.org/10.1056/NEJMoa1106173
- Whyte MP, Madson KL, Phillips D, Reeves AL, McAlister WH, Yakimoski A, et al. Asfotase alfa therapy for children with hypophosphatasia. JCI Insight 2016;1:e85971.
- Kim I, Noh ES, Kim MS, Jang JH, Jeon TY, Choi HW, et al. Six-year clinical outcomes of enzyme replacement therapy for perinatal lethal and infantile hypophosphatasia in Korea: Two case reports. Medicine (Baltimore) 2023;102:e32800.
- Michigami T, Ohata Y, Fujiwara M, Mochizuki H, Adachi M, Kitaoka T, et al. Clinical Practice Guidelines for Hypophosphatasia. Clin Pediatr Endocrinol 2020;29:9-24. https://doi.org/10.1297/cpe.29.9
- Kawahara T, Watanabe H, Omae R, Yamamoto T, Inazu T. A Novel PHEX Mutation in Japanese Patients with X-Linked Hypophosphatemic Rickets. Case Rep Genet 2015;2015:301264.
- Jagtap VS, Sarathi V, Lila AR, Bandgar T, Menon P, Shah NS. Hypophosphatemic rickets. Indian J Endocrinol Metab 2012;16:177-82. https://doi.org/10.4103/2230-8210.93733
- Brodehl J. Assessment and interpretation of the tubular threshold for phosphate in infants and children. Pediatr Nephrol 1994;8:645.
- Linglart A, Biosse-Duplan M, Briot K, Chaussain C, Esterle L, Guillaume-Czitrom S, et al. Therapeutic management of hypophosphatemic rickets from infancy to adulthood. Endocr Connect 2014;3:R13-30. https://doi.org/10.1530/EC-13-0103
- Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL. A clinician's guide to X-linked hypophosphatemia. J Bone Miner Res 2011;26:1381-8. https://doi.org/10.1002/jbmr.340
- Morey M, Castro-Feijoo L, Barreiro J, Cabanas P, Pombo M, Gil M, et al. Genetic diagnosis of X-linked dominant Hypophosphatemic Rickets in a cohort study: tubular reabsorption of phosphate and 1,25 (OH)2D serum levels are associated with PHEX mutation type. BMC Med Genet 2011;12:116.
- Barneveld RA, Keijzer W, Tegelaers FP, Ginns EI, Geurts van Kessel A, Brady RO, et al. Assignment of the gene coding for human beta-glucocerebrosidase to the region q21-q31 of chromosome 1 using monoclonal antibodies. Hum Genet 1983;64:227-31. https://doi.org/10.1007/BF00279398
- Kaplan P, Andersson HC, Kacena KA, Yee JD. The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis. Arch Pediatr Adolesc Med 2006;160:603-8. https://doi.org/10.1001/archpedi.160.6.603
- Gupta N, Oppenheim IM, Kauvar EF, Tayebi N, Sidransky E. Type 2 Gaucher disease: phenotypic variation and genotypic heterogeneity. Blood Cells Mol Dis 2011;46:75-84. https://doi.org/10.1016/j.bcmd.2010.08.012
- In: Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, et al., eds. GeneReviews(®): Copyright © 1993-2023, University of Washington, Seattle., 1993.
- Wenstrup RJ, Roca-Espiau M, Weinreb NJ, Bembi B. Skeletal aspects of Gaucher disease: a review. Br J Radiol 2002;75 Suppl 1:A2-12. https://doi.org/10.1259/bjr.75.suppl_1.750002
- Pastores GM, Patel MJ, Firooznia H. Bone and joint complications related to Gaucher disease. Curr Rheumatol Rep 2000;2:175-80. https://doi.org/10.1007/s11926-000-0059-x
- Cohen IJ. Bone crises in Gaucher disease. Isr Med Assoc J 2003;5:838-9.
- Vellodi A, Tylki-Szymanska A, Davies EH, Kolodny E, Bembi B, Collin-Histed T, et al. Management of neuronopathic Gaucher disease: revised recommendations. J Inherit Metab Dis 2009;32:660-4. https://doi.org/10.1007/s10545-009-1164-2
- Mistry PK, Sadan S, Yang R, Yee J, Yang M. Consequences of diagnostic delays in type 1 Gaucher disease: the need for greater awareness among hematologists-oncologists and an opportunity for early diagnosis and intervention. Am J Hematol 2007;82:697-701. https://doi.org/10.1002/ajh.20908
- Muenzer J. Overview of the mucopolysaccharidoses. Rheumatology (Oxford) 2011;50 Suppl 5:v4-12. https://doi.org/10.1093/rheumatology/ker394
- Spranger J. Bone dysplasia 'families'. Pathol Immunopathol Res 1988;7:76-80. https://doi.org/10.1159/000157098
- Guarany NR, Schwartz IV, Guarany FC, Giugliani R. Functional capacity evaluation of patients with mucopolysaccharidosis. J Pediatr Rehabil Med 2012;5:37-46. https://doi.org/10.3233/PRM-2012-0194
- Tomatsu S, Yasuda E, Patel P, Ruhnke K, Shimada T, Mackenzie WG, et al. Morquio A syndrome: diagnosis and current and future therapies. Pediatr Endocrinol Rev 2014;12 Suppl 1:141-51.
- Langereis EJ, den Os MM, Breen C, Jones SA, Knaven OC, Mercer J, et al. Progression of Hip Dysplasia in Mucopolysaccharidosis Type I Hurler After Successful Hematopoietic Stem Cell Transplantation. J Bone Joint Surg Am 2016;98:386-95. https://doi.org/10.2106/JBJS.O.00601
- Brands MM, Gungor D, van den Hout JM, Karstens FP, Oussoren E, Plug I, et al. Pain: a prevalent feature in patients with mucopolysaccharidosis. Results of a cross-sectional national survey. J Inherit Metab Dis 2015;38:323-31. https://doi.org/10.1007/s10545-014-9737-0
- Peracha H, Sawamoto K, Averill L, Kecskemethy H, Theroux M, Thacker M, et al. Molecular genetics and metabolism, special edition: Diagnosis, diagnosis and prognosis of Mucopolysaccharidosis IVA. Mol Genet Metab 2018;125:18-37. https://doi.org/10.1016/j.ymgme.2018.05.004
- Harmatz P, Ketteridge D, Giugliani R, Guffon N, Teles EL, Miranda MC, et al. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics 2005;115:e681-9. https://doi.org/10.1542/peds.2004-1023
- Hendriksz CJ. Elosulfase alfa (BMN 110) for the treatment of mucopolysaccharidosis IVA (Morquio A Syndrome). Expert Rev Clin Pharmacol 2016;9:1521-32. https://doi.org/10.1080/17512433.2017.1260000
- Kakkis ED, Muenzer J, Tiller GE, Waber L, Belmont J, Passage M, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 2001;344:182-8. https://doi.org/10.1056/NEJM200101183440304
- Fox JE, Volpe L, Bullaro J, Kakkis ED, Sly WS. First human treatment with investigational rhGUS enzyme replacement therapy in an advanced stage MPS VII patient. Mol Genet Metab 2015;114:203-8. https://doi.org/10.1016/j.ymgme.2014.10.017
- Muenzer J, Beck M, Eng CM, Giugliani R, Harmatz P, Martin R, et al. Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome. Genet Med 2011;13:95-101. https://doi.org/10.1097/GIM.0b013e3181fea459
- Jakobkiewicz-Banecka J, Gabig-Ciminska M, Kloska A, Malinowska M, Piotrowska E, Banecka-Majkutewicz Z, et al. Glycosaminoglycans and mucopolysaccharidosis type III. Front Biosci (Landmark Ed) 2016;21:1393-409. https://doi.org/10.2741/4463
- Schweighardt B, Tompkins T, Lau K, Jesaitis L, Qi Y, Musson DG, et al. Immunogenicity of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients With Morquio A Syndrome: Results From MOR-004, a Phase III Trial. Clin Ther 2015;37:1012-21.e6. https://doi.org/10.1016/j.clinthera.2014.11.005